# US 2006/0051772 A1 · SSX-4 peptides presented by HLA class II molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051772 A1
- Document ID: US20060051772A1
- Status: Published application
- Kind: A1
- Application number: 10/936,888
- Filed: 2004-09-09
- Published: 2006-03-09
- Earliest claimed: 2004-09-09
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Danila Valmori; Maha Ayyoub
- Web page: https://patentgrep.com/patent/US20060051772A1

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/30: from tumour cells
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-4 gene.

## Claims

### Claim 1

An isolated SSX-4 HLA class II-binding peptide comprising an amino acid sequence selected from the group set forth as SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or a functional variant thereof comprising 1-5 amino acid substitutions, wherein the HLA class II-binding peptide does not include a full length SSX-4 protein.

### Claim 2 (depends on 1)

The isolated HLA class II-binding peptide of claim 1, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10

### Claim 3 (depends on 2)

The isolated HLA class II-binding peptide of claim 2, wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

### Claim 4 (depends on 1)

The isolated HLA class II-binding peptide of claim 1, wherein the isolated peptide comprises an endosomal targeting signal.

### Claim 5 (depends on 4)

The isolated HLA class II-binding peptide of claim 4, wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain Ii.

### Claim 6 (depends on 1)

The isolated HLA class II-binding peptide of claim 1, wherein the isolated peptide is non-hydrolyzable.

### Claim 7 (depends on 6)

The isolated HLA class II-binding peptide of claim 6, wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH2NH]-reduced amide peptide bond, peptides comprising a -psi[COCH2]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH2CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH2O]-peptide bond, and peptides comprising a -psi[CH2S]-thiomethylene peptide bond.

### Claim 8

A composition comprising an isolated HLA class I-binding peptide and an isolated SSX-4 HLA class II-binding peptide, wherein the isolated SSX-4 HLA class II-binding peptide comprises an amino acid sequence selected from the group set forth as SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, or a functional variant thereof comprising 1-5 amino acid substitutions, and wherein the HLA class II binding peptide does not include the full length SSX-4 protein.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the HLA class I-binding peptide and the SSX-4 HLA class II-binding peptide are combined as a polytope polypeptide.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the isolated SSX-4 HLA class II-binding peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

### Claim 11 (depends on 8)

The composition of claim 8, wherein the isolated SSX-4 HLA class II-binding peptide comprises an endosomal targeting signal.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain Ii.

### Claim 13 (depends on 1)

A composition comprising one or more of the isolated SSX-4 HLA class II-binding peptides of claim 1 complexed with one or more isolated HLA class II molecules.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the number of isolated SSX-4 HLA class II-binding peptides and the number of isolated HLA class II molecules are equal.

### Claim 15 (depends on 13)

The method of claim 13, wherein the isolated SSX-4 HLA class II-binding peptides and the isolated HLA class II molecules are coupled as a tetrameric molecule of individual isolated SSX-4 HLA class II-binding peptides bound to individual isolated HLA class II molecules.

### Claim 16 (depends on 15)

The method of claim 15, wherein the HLA class II molecules are DR molecules.

### Claim at position 17

-74. (canceled)
